Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention

被引:71
作者
Armstrong, Paul W. [1 ]
Fu, Yuling
Westerhout, Cynthia M.
Hudson, Michael P. [2 ]
Mahaffey, Kenneth W. [3 ]
White, Harvey D. [4 ]
Todaro, Thomas G. [5 ]
Adams, Peter X. [6 ]
Aylward, Philip E. G. [7 ]
Granger, Christopher B. [3 ]
机构
[1] Univ Alberta, Dept Med, Div Cardiol, Edmonton, AB T6G 2H7, Canada
[2] Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA
[3] Duke Clin Res Inst, Durham, NC USA
[4] Green Lane Coordinating Ctr, Auckland, New Zealand
[5] Procter & Gamble Hlth Care Res Ctr, Mason, OH USA
[6] Alexion Pharmaceut, Cheshire, CT USA
[7] Flinders Med Ctr, Bedford Pk, SA, Australia
关键词
infarction; prognosis; Q-wave; APEX-AMI; PEXELIZUMAB; THERAPY; TRIAL; RESOLUTION; MORTALITY; EFFICACY; INSIGHTS;
D O I
10.1016/j.jacc.2009.01.046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We assessed the incremental value of baseline Q waves over time from symptom onset as a marker of clinical outcome in ST-segment elevation myocardial infarction (STEMI). Background Time from symptom onset is a central focus in STEMI patients. The presence of Q waves on the baseline electrocardiogram (ECG) has been suggested to be of incremental value to time from symptom onset in evaluating clinical outcomes. Methods We evaluated baseline Q waves and ST-segment resolution 30 min after primary percutaneous intervention (PCI) ECGs in 4,530 STEMI patients without prior infarction. Additionally, peak biomarkers; 90-day mortality; and the composite of death, congestive heart failure (CHF), or cardiogenic shock were assessed. Results Fifty-six percent of patients had baseline Q waves: they were older, more frequently male and diabetic, and had a more advanced Killip class. Patients with baseline Q waves had greater mortality and a higher composite rate of death, CHF, and shock versus patients without baseline Q waves at 90 days (5.3% vs. 2.1% and 12.1% vs. 4.8%, respectively, both p < 0.001). Complete ST- segment resolution was highest, whereas 90-day mortality and the composite outcome were lowest among those randomized <= 3 h without baseline Q waves. After multivariable adjustment, baseline Q-wave but not time from symptom onset was significantly associated with a 78% relative increase in the hazard of 90-day mortality and a 90% relative increase in the hazard of death, shock, and CHF. Conclusions Baseline Q waves in STEMI patients treated with primary PCI provide an independent prognostic marker of clinical outcome. These data might be useful in designing future clinical trials as well as in evaluating patients for triage and potential transfer for planned primary PCI. (Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction [APEX-AMI]; NCT00091637) (J Am Coll Cardiol 2009;53:1503-9) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:1503 / 1509
页数:7
相关论文
共 15 条
[1]   EVALUATION OF A QRS SCORING SYSTEM FOR ESTIMATING MYOCARDIAL INFARCT SIZE .6. IDENTIFICATION OF SCREENING CRITERIA FOR NON-ACUTE MYOCARDIAL INFARCTS [J].
ANDERSON, WD ;
WAGNER, NB ;
LEE, KL ;
WHITE, RD ;
YUSCHAK, J ;
BEHAR, VS ;
SELVESTER, RH ;
IDEKER, RE ;
WAGNER, GS .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 61 (10) :729-733
[2]   New Q waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction [J].
Andrews, J ;
French, JK ;
Manda, SOM ;
White, HD .
EUROPEAN HEART JOURNAL, 2000, 21 (08) :647-653
[3]  
Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002
[4]  
Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43
[5]   Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [J].
Armstrong, PW ;
Adams, PX ;
Al-Khalidi, HR ;
Hamm, C ;
Holmes, D ;
O'Neill, W ;
Todaro, TG ;
Vahanian, A ;
Van de Werf, F ;
Granger, CB .
AMERICAN HEART JOURNAL, 2005, 149 (03) :402-407
[6]   ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction - Insights from the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial [J].
Buller, Christopher E. ;
Fu, Yuling ;
Mahaffey, Kenneth W. ;
Todaro, Thomas G. ;
Adams, Peter ;
Westerhout, Cynthia M. ;
White, Harvey D. ;
Hof, Arnoud W. J. Van 't ;
De Werf, Frans J. Van ;
Wagner, Galen S. ;
Granger, Christopher B. ;
Armstrong, Paul W. .
CIRCULATION, 2008, 118 (13) :1335-1346
[7]  
JENNINGS RB, 1983, CIRCULATION, V68, P25
[8]   Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy [J].
Lockwood, E ;
Fu, YL ;
Wong, B ;
Van de Werf, F ;
Granger, CB ;
Armstrong, PW ;
Goodman, SG .
AMERICAN HEART JOURNAL, 2003, 146 (04) :640-645
[9]   Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy [J].
McDonald, Michael A. ;
Fu, Yuling ;
Zeymer, Uwe ;
Wagner, Galen ;
Goodman, Shaun G. ;
Ross, Allan ;
Granger, Christopher B. ;
de Werf, Frans Van ;
Armstrong, Paul W. .
EUROPEAN HEART JOURNAL, 2008, 29 (07) :871-879
[10]   Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: Does the choice of fibrinolytic agent impact on the importance of time-to-treatment? [J].
Nallamothu, BK ;
Antman, EM ;
Bates, ER .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (06) :772-774